浙江震元(000705) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of between 26.13 million and 36.58 million yuan for 2024, a decrease of 55.2% to 68% compared to the previous year’s profit of 81.64 million yuan[3] - The basic earnings per share are projected to be between 0.08 yuan and 0.11 yuan, down from 0.24 yuan per share in the same period last year[3] - The decline in profit is primarily due to a focus on the pharmaceutical sector, increased R&D investment, and strategic adjustments, leading to reduced sales in the pharmaceutical wholesale business[5] - New bank loans have increased financial expenses, further impacting the company's profit[6] Accounts Receivable and Sales - The company has experienced an increase in accounts receivable due to slower hospital payments, resulting in higher credit impairment compared to the previous year[6] - The pharmaceutical retail sector has seen a decline in sales of high-margin products, contributing to a decrease in gross profit[6] Strategic Development - The company is actively developing synthetic biology projects and accelerating project construction[5] Performance Forecast - The performance forecast is preliminary and has not been audited by the accounting firm, with final figures to be disclosed in the 2024 annual report[7]